Publications by authors named "D K Hyslop"
Article Synopsis
- - Nirogacestat is an FDA-approved drug for treating desmoid tumors in adults, but a phase 3 study revealed that it can cause ovarian toxicity (OT) in females capable of reproduction, which necessitated further investigation into its effects.
- - In this study, 75% of women taking nirogacestat experienced OT, while none in the placebo group did; the average duration of OT was about 19 weeks, but most patients saw resolution of symptoms after stopping the drug or while on treatment.
- - The findings suggest that although ovarian toxicity is common among those treated with nirogacestat, it tends to be temporary, with many patients recovering their menstrual cycles and hormonal levels after either stopping the medication or
Objectives: To evaluate the incidence of infection in patients with active rheumatoid arthritis (RA) treated with baricitinib, an oral selective Janus kinase (JAK)1 and JAK2 inhibitor.
Methods: Infections are summarised from an integrated database (8 phase 3/2/1b clinical trials and 1 long-term extension (LTE)) with data to 1 April 2017. The 'all-bari-RA' analysis set included patients who received any baricitinib dose.
Effects of results-based financing of maternal and child health services on patient satisfaction in Afghanistan.
J Health Serv Res Policy
January 2019
Objective: To examine the impact of a results-based financing programme on patient satisfaction in Afghanistan.
Methods: We analysed data collected from over 3000 patients from a stratified sample of 112 health facilities (56 results-based financing and 56 non-results-based financing) in 11 out of the 34 provinces of Afghanistan over a three-year period. The 112 facilities were part of 442 primary care facilities that were stratified on facility type and randomly assigned to the results-based financing (intervention) and non-results-based financing (control) groups in the 11 provinces.
Objective: Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA). We evaluated baricitinib's safety profile through 288 weeks (up to September 1, 2016) with an integrated database [8 phase III/II/Ib trials, 1 longterm extension (LTE)].
Methods: The "all-bari-RA" group included patients who received any baricitinib dose.
Background: Children with incarcerated mothers experience adverse health, social and emotional circumstances, and are a particularly vulnerable group. Mothers in custody face significant challenges in parenting their children.
Aims: The study aimed to identify participants' views on impact of a parenting support programme for incarcerated mothers in NSW Australia.